<DOC>
	<DOCNO>NCT02189304</DOCNO>
	<brief_summary>This single-center , Phase I , healthy adult subject study randomize , double blind , three period , three-treatment , cross-over design .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study PT010 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Informed Consent Form ( ICF ) prior study related procedure Male female subject 18 55 year , inclusive Good general health Medically acceptable contraception woman childbearing potential male female partner childbearing potential Clinical lab within normal range determine clinically significant Investigator Pregnancy , nurse female subject , subject try conceive Clinically significant neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematological , psychiatric , medical illness would interfere participation study History ECG abnormalities Cancer complete remission least 5 year Clinically significant , symptomatic prostatic hypertrophy Male subject transurethral resection prostate full resection prostate within 6 month prior Screening Clinically significant bladder neck obstruction urinary retention Inadequately treat glaucoma History allergic reaction hypersensitivity drug component formulation use study Subjects preexist anemia and/or iron deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>